Related Experiment Video

Updated: May 1, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Protein kinase inhibitors to treat non-small-cell lung cancer

Gabriele Minuti1, Armida D'Incecco, Lorenza Landi

  • 1Istituto Toscano Tumori, Ospedale Civile, Oncologia Medica , Viale Alfieri 36, 57100-Livorno , Italy +39 0586223189 ; +39 0586223457 ; f.cappuzzo@gmail.com.

Expert Opinion on Pharmacotherapy
|April 22, 2014
PubMed
Abstract

Insights

Targeted therapies like EGFR TKIs and ALK inhibitors are crucial for non-small cell lung cancer (NSCLC). These molecularly targeted drugs offer superior outcomes for patients with specific genetic mutations compared to traditional chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Activating mutations in the Epidermal Growth Factor Receptor (EGFR) and rearrangements of Anaplastic Lymphoma Kinase (ALK) are key molecular drivers in non-small cell lung cancer (NSCLC).
  • Molecular characterization is therapeutically relevant for NSCLC patient stratification.

Purpose of the Study:

  • To review and analyze Phase III clinical trials evaluating tyrosine kinase inhibitors (TKIs) in NSCLC treatment.
  • To assess the efficacy and therapeutic relevance of TKIs in specific NSCLC molecular subtypes.

Main Methods:

  • Systematic collection and analysis of published data from relevant Phase III trials.
  • Focus on trials involving tyrosine kinase inhibitors (TKIs) for NSCLC treatment.

Main Results:

  • EGFR TKIs are established as the optimal first-line therapy for EGFR-mutated NSCLC.
  • In pretreated NSCLC, EGFR TKIs show greater efficacy than cytotoxic monotherapy for EGFR-mutated patients.
  • For EGFR wild-type NSCLC, EGFR TKIs demonstrate survival efficacy comparable to docetaxel or pemetrexed.
  • A multi-target TKI targeting ALK demonstrated superiority over standard chemotherapy in ALK-translocated NSCLC regarding progression-free survival, response rate, and toxicity.

Conclusions:

  • EGFR TKIs represent a cornerstone of therapy for EGFR-mutated NSCLC.
  • Targeted therapy for ALK-translocated NSCLC significantly improves outcomes compared to chemotherapy.
  • Ongoing research focuses on novel agents for EGFR and ALK, particularly addressing acquired resistance to existing TKIs.
Keywords:
NSCLCafatinibcrizotiniberlotinibgefitinib

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K